Scarica l'app Stockscreener
20.89
2.93%
-0.63
Dopo l'orario di chiusura:
20.86
-0.03
-0.14%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché ACAD Giù?
Forum
Previsione
Acadia Pharmaceuticals Inc Borsa (ACAD) Ultime notizie
Baker funds tied to ACAD (ACAD) report RSU and stock option grants - Stock Titan
Technical Reactions to ACAD Trends in Macro Strategies - Stock Traders Daily
ACAD Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
ACADIA Pharmaceuticals (ACAD) director receives new RSUs and stock option grant - Stock Titan
ACADIA (NASDAQ: ACAD) director Adora Ndu exercises RSUs and receives new option, RSU grants - Stock Titan
ACADIA (NASDAQ: ACAD) director receives RSUs and $21.66 stock options - Stock Titan
ACADIA (NASDAQ: ACAD) director granted RSUs, options and exercises into shares - Stock Titan
ACADIA (ACAD) director Garofalo exercises RSUs and receives new option, RSU awards - Stock Titan
ACADIA (NASDAQ: ACAD) director granted RSUs and stock options - Stock Titan
Acadia Shareholders Approve Directors, Executive Pay and Equity Plan - The Globe and Mail
A Quick Look at Today's Ratings for ACADIA Pharmaceuticals(ACAD.US), With a Forecast Between $24 to $38 - Moomoo
Acadia Pharmaceuticals (NASDAQ: ACAD) investors approve 5.2M-share boost to 2024 equity plan - Stock Titan
ACAD Stock Price, Quote & Chart | ACADIA PHARMACEUTICALS INC (NASDAQ:ACAD) - ChartMill
Principal Accounting Officer At ACADIA Pharmaceuticals Sells $114K Of Stock - Benzinga
Biopharmas look to China, elsewhere for partnerships, R&D - MSN
Insider Sell: James Kihara Sells Shares of ACADIA Pharmaceuticals Inc (ACAD) - GuruFocus
Acadia principal accounting officer Kihara sells $114,393 stock - Investing.com UK
[Form 4] ACADIA PHARMACEUTICALS INC Insider Trading Activity - Stock Titan
ACADIA Pharmaceuticals (ACAD) Holds Near Support as Price Action ConsolidatesDiagonal Spread Trade - thelegaladvocate.com
ACADIA Pharmaceuticals targets $1B brand opportunity as key neuropsychiatry data looms - MSN
Form 144 lists 3,857 performance shares and ESPP lots for ACAD (NASDAQ: ACAD) - Stock Titan
Acadia Pharmaceuticals (ACAD) lags Q1 earnings and revenue estimates - MSN
Acadia boosts ‘More To Parkinson's’ campaign with Ryan Reynolds, Parkinson’s voices - Fierce Pharma
Acadia Pharmaceuticals’ SWOT analysis: stock faces EU hurdle By Investing.com - Investing.com Canada
Trading the Move, Not the Narrative: (ACAD) Edition - Stock Traders Daily
Assessing ACADIA Pharmaceuticals (ACAD) Valuation After Pipeline Progress And Product Rollouts - Sahm
Acadia Pharmaceuticals’ SWOT analysis: stock faces EU hurdle - Investing.com UK
ACAD Technical Analysis | Trend, Signals & Chart Patterns | ACADIA PHARMACEUTICALS INC (NASDAQ:ACAD) - ChartMill
Acadia launches powder version of Rett syndrome treatment in the US - MSN
ACAD: Remlifanserin advances in ADP, NUPLAZID expands reach, and DAYBUE STIX boosts patient persistence - TradingView
ACADIA Pharmaceuticals Spotlights Alzheimer’s Psychosis Pipeline, NUPLAZID and DAYBUE Growth - Barchart.com
How ACADIA’s (ACAD) Solid Q1 Revenue and Pipeline Update Has Changed Its Investment Story - simplywall.st
Acadia Pharmaceuticals (ACAD) CEO Highlights Global R&D Partners - GuruFocus
Biopharmas look to China, elsewhere for partnerships, R&D (ACAD:NASDAQ) - Seeking Alpha
ACADIA Pharmaceuticals stock (US0042251084): Biotech decline amid CNS focus - AD HOC NEWS
Shareholders In ACADIA Pharmaceuticals (NASDAQ:ACAD) Should Look Beyond Earnings For The Full Story - Yahoo Finance
Earnings call transcript: ACADIA Q1 2026 misses forecasts, stock steady By Investing.com - Investing.com Australia
Earnings call transcript: ACADIA Q1 2026 misses forecasts, stock steady - Investing.com
2.89%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):